OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Rohini Khilian

4 Projects | 1 Researchers | $1,082,000 Invested

2021

Foundation for the National Institutes of Health, Inc.

Rohini Khilian

Neurofilament (Nf) as a Fluid Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (f-FTD)

  • Funding Amount: $280,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Neuronal Degeneration
  • Status: Active

2020

Foundation for the National Institutes of Health, Inc.

Rohini Khilian

Pre-competitive Analytical Validation of SV2A PET as a Biomarker of Synaptic Density Project

  • Funding Amount: $300,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Active

2020

Foundation for the National Institutes of Health, Inc.

Rohini Khilian

Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer’s Disease

  • Funding Amount: $402,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: zzAbeta
  • Status: Active

2018

Foundation for the National Institutes of Health, Inc.

Rohini Khilian

Inflammatory Markers for Early Detection & Subtyping of Neurodegenerative & Mood Disorders

  • Funding Amount: $100,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Neuroinflammation
  • Status: Active